DE69917937D1 - Formulierungen mit gesteuerter freisetzung, die einen schnellen eintritt und einen schnellen abfall der wirksamen arzneistoffplasmakonzentrationen haben - Google Patents

Formulierungen mit gesteuerter freisetzung, die einen schnellen eintritt und einen schnellen abfall der wirksamen arzneistoffplasmakonzentrationen haben

Info

Publication number
DE69917937D1
DE69917937D1 DE69917937T DE69917937T DE69917937D1 DE 69917937 D1 DE69917937 D1 DE 69917937D1 DE 69917937 T DE69917937 T DE 69917937T DE 69917937 T DE69917937 T DE 69917937T DE 69917937 D1 DE69917937 D1 DE 69917937D1
Authority
DE
Germany
Prior art keywords
fast
controlled release
release formulations
plasma concentrations
admission
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69917937T
Other languages
English (en)
Other versions
DE69917937T2 (de
Inventor
N Krishnamurthy
Andrew Darke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22344918&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69917937(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Application granted granted Critical
Publication of DE69917937D1 publication Critical patent/DE69917937D1/de
Publication of DE69917937T2 publication Critical patent/DE69917937T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
DE69917937T 1998-12-17 1999-12-17 Formulierungen mit gesteuerter freisetzung, die einen schnellen eintritt und einen schnellen abfall der wirksamen arzneistoffplasmakonzentrationen haben Expired - Lifetime DE69917937T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11261798P 1998-12-17 1998-12-17
US112617P 1998-12-17
PCT/IB1999/002095 WO2000035426A2 (en) 1998-12-17 1999-12-17 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations

Publications (2)

Publication Number Publication Date
DE69917937D1 true DE69917937D1 (de) 2004-07-15
DE69917937T2 DE69917937T2 (de) 2005-05-25

Family

ID=22344918

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69917937T Expired - Lifetime DE69917937T2 (de) 1998-12-17 1999-12-17 Formulierungen mit gesteuerter freisetzung, die einen schnellen eintritt und einen schnellen abfall der wirksamen arzneistoffplasmakonzentrationen haben

Country Status (12)

Country Link
US (11) US6419960B1 (de)
EP (1) EP1143937B1 (de)
JP (1) JP4172917B2 (de)
AT (1) ATE268595T1 (de)
AU (1) AU2122700A (de)
CA (1) CA2355854C (de)
DE (1) DE69917937T2 (de)
DK (1) DK1143937T3 (de)
ES (1) ES2224740T3 (de)
PT (1) PT1143937E (de)
SI (1) SI1143937T1 (de)
WO (1) WO2000035426A2 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
NZ511442A (en) * 1998-11-02 2003-02-28 Elan Corp Plc Multiparticulate modified release composition for multiple dosing of ADD patients with methylphenidate HCl
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US7083808B2 (en) * 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6673367B1 (en) 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
EP2295043A1 (de) 1999-10-29 2011-03-16 Euro-Celtique S.A. Hydrocodon-Formulierungen mit gesteuerter Freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
DE60115840T2 (de) * 2000-01-19 2006-07-13 Mannkind Corp., Danbury Formulierung mit mehrfach gepulster wirkstofffreisetzung
GB0007419D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6344215B1 (en) * 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
KR101167465B1 (ko) 2000-10-30 2012-07-27 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
JP3943342B2 (ja) * 2001-03-26 2007-07-11 富士通株式会社 診療実績情報作成プログラム、医薬品情報処理プログラム、診療実績情報作成方法、医薬品情報システム
CA2447008A1 (en) * 2001-04-05 2002-10-24 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20030099711A1 (en) * 2001-08-29 2003-05-29 David Meadows Sustained release preparations
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20040037879A1 (en) * 2001-11-02 2004-02-26 Adusumilli Prasad S. Oral controlled release forms useful for reducing or preventing nicotine cravings
NL1021822C2 (nl) * 2001-11-07 2003-07-15 Synthon Bv Tamsulosinetabletten.
AU2003246792B2 (en) 2002-04-09 2008-08-28 Flamel Ireland Limited Oral suspension of active principle microcapsules
IL164221A0 (en) * 2002-04-09 2005-12-18 Flamel Tech Sa Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillim
CA2395819A1 (en) * 2002-08-13 2004-02-13 Bernard Charles Sherman Dual-spike release formulation for oral drug delivery
US6913768B2 (en) 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
HUE026034T2 (en) 2002-12-13 2016-05-30 Durect Corp Oral delivery system containing an oral high-viscosity carrier
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
NZ546148A (en) 2003-09-26 2009-05-31 Alza Corp Drug coating providing high drug loading and methods for providing the same
US7691880B2 (en) * 2003-10-08 2010-04-06 Mallinckrodt Inc. Methylphenidate solution and associated methods of administration and production
US7410978B2 (en) * 2003-11-04 2008-08-12 Supernus Pharmaceuticals, Inc. Once daily dosage forms of trospium
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
DE602004014723D1 (de) * 2004-04-30 2008-08-14 Desitin Arzneimittel Gmbh Histondeacetylase-Inhibitor enthaltende Formulierung zur zweiphasigen Freisetzung
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
ES2261006B1 (es) * 2004-06-10 2007-11-01 Laboratorios Rubio, S.A. Pellet multicapa de liberacion controlada de metilfenidato.
US9308164B2 (en) 2004-06-30 2016-04-12 Sovereign Pharmaceuticals, Llc Hyoscyamine dosage form
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
ES2314693T3 (es) * 2004-08-23 2009-03-16 PEJO ISERLOHN HEILMITTEL-UND DIAT-GMBH & CO.KG Composicion farmaceutica que contiene psicoestimulantes.
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
WO2006063078A2 (en) * 2004-12-08 2006-06-15 Elan Corporation, Plc Topiramate pharmaceuticals composition
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EA200702221A1 (ru) * 2005-04-12 2008-04-28 Элан Фарма Интернэшнл Лимитед Композиции с контролируемым высвобождением для лечения бактериальной инфекции, содержащие цефалоспорин
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
WO2007037790A2 (en) * 2005-06-08 2007-04-05 Elan Corporation, Plc Modified release famciclovir compositions
US20070020333A1 (en) * 2005-07-20 2007-01-25 Chin-Chih Chiang Controlled release of hypnotic agents
US20070104788A1 (en) * 2005-11-10 2007-05-10 Seamus Mulligan Once-daily administration of central nervous system drugs
WO2007109104A2 (en) 2006-03-16 2007-09-27 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
US20070253927A1 (en) * 2006-04-13 2007-11-01 Gwenaelle Jegou Cosmetic compositions comprising at least one dielectrophile monomer and at least one radical initiator
WO2008011596A2 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophilic abuse deterrent delivery system
WO2009088414A2 (en) 2007-12-06 2009-07-16 Durect Corporation Oral pharmaceutical dosage forms
JP2011529923A (ja) 2008-08-06 2011-12-15 ゴスフォース センター（ホールディングス）プロプライエタリー リミテッド 精神障害（ｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒ）を治療するための組成物および方法
US20100260844A1 (en) * 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
WO2011020032A2 (en) * 2009-08-13 2011-02-17 Kudco Ireland, Ltd. Pharmaceutical dosage form
US20110052700A1 (en) * 2009-08-31 2011-03-03 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of levosulpiride
CA2812570A1 (en) * 2010-09-24 2012-03-29 QRxPharma Ltd. Controlled release formulations of opioids
AU2011346758C1 (en) 2010-12-23 2015-09-03 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
CA2830788C (en) * 2011-03-23 2016-05-17 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
NO2736497T3 (de) 2011-07-29 2018-01-20
KR20140053159A (ko) 2011-07-29 2014-05-07 그뤼넨탈 게엠베하 즉시 약물 방출을 제공하는 탬퍼-저항성 정제
DE102012105528A1 (de) * 2012-06-25 2014-01-02 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur Freisetzung von Wirkstoffen
CA2880456A1 (en) 2012-08-15 2014-02-20 Tris Pharma, Inc. Methylphenidate extended release chewable tablet
EP2906208B1 (de) * 2012-10-09 2019-01-30 Sears, Douglas Therapeutische behandlung
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
KR20160031526A (ko) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형
CA2936741C (en) * 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
KR20170132325A (ko) 2015-04-02 2017-12-01 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 뮤 오피오이드 수용체 길항제 및 오피오이드 제제의 조합 제형
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US9875113B2 (en) * 2015-12-09 2018-01-23 Quanta Computer Inc. System and method for managing BIOS setting configurations
GB201610101D0 (en) * 2016-06-09 2016-07-27 Attenborough Dental Laboratories Ltd Multicellular lay-up process
EP3372225A1 (de) * 2017-03-09 2018-09-12 Develco Pharma Schweiz AG Neuartige darreichungsform
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
WO2019071272A1 (en) * 2017-10-06 2019-04-11 Adare Pharmaceuticals, Inc. PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY (ADHD)
US20190110992A1 (en) * 2017-10-13 2019-04-18 Grünenthal GmbH Modified release abuse deterrent dosage forms
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN111557929B (zh) * 2020-05-15 2021-12-07 河南中帅医药科技股份有限公司 一种盐酸右哌甲酯多重释放制剂及其制备方法
AU2022345789A1 (en) * 2021-09-14 2024-03-28 Nulixir Inc. Alimentary-related particles, production methods, and production apparatus

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
JPS55149211A (en) 1979-05-10 1980-11-20 Takeda Chem Ind Ltd Production of gradually releasable preparation
GB2186485B (en) 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
AU591248B2 (en) * 1986-03-27 1989-11-30 Kinaform Technology, Inc. Sustained-release pharaceutical preparation
US4842867A (en) 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
DE3769707D1 (de) 1986-06-17 1991-06-06 Recordati Chem Pharm Therapeutisches system mit geregelter wirkstoffabgabe.
IT1213080B (it) 1986-06-17 1989-12-07 Recordati Chem Pharm Sistemi terapeutico per la cessione controllata di farmaci.
US4786503A (en) 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
EP0325086A3 (de) 1987-11-23 1990-10-31 Jago Research Ag Verfahren zur Herstellung von therapeutischen Systemen mit gesteuerter Freigabe des Wirkstoffes
DE3827214A1 (de) 1988-08-11 1990-02-15 Roehm Gmbh Retardierte arzneiform und verfahren zu ihrer herstellung
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5643602A (en) 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
IE61651B1 (en) 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
US5156850A (en) 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
WO1992021333A2 (en) 1991-05-24 1992-12-10 Pharmavene, Inc. Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors
EP0520119A1 (de) * 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Neue orale Diclofenaczubereitung
US5326570A (en) 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
JPH072650A (ja) 1993-06-18 1995-01-06 Tanabe Seiyaku Co Ltd 放出部位制御型製剤
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US6077533A (en) * 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
US5658590A (en) 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
MXPA98000395A (es) 1995-07-14 2005-04-29 Medeva Europ Ltd Composicion que comprende d-treo-metilfenidato y otra droga.
GB9514451D0 (en) 1995-07-14 1995-09-13 Chiroscience Ltd Sustained-release formulation
JPH11509227A (ja) 1995-07-14 1999-08-17 カイロサイエンス・リミテッド ｄ−トレオ−メチルフェニデートの治療的使用
US5922736A (en) 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
AU695734B2 (en) * 1996-07-08 1998-08-20 Penwest Pharmaceuticals Co. Sustained release matrix for high-dose insoluble drugs
WO1998006380A2 (en) 1996-08-16 1998-02-19 Alza Corporation Dosage form for providing ascending dose of drug
CA2264852C (en) 1996-09-30 2005-11-01 Alza Corporation Use of methylphenidate or a pharmaceutically acceptable salt thereof
US5851579A (en) 1996-10-28 1998-12-22 Eastman Chemical Company Aqueous enteric coating compositions
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
ES2264173T3 (es) 1996-11-25 2006-12-16 Alza Corporation Forma de dosificacion para suministrar una dosis creciente.
DE19718012C1 (de) 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
US5885616A (en) 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
US6372254B1 (en) 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US5945123A (en) * 1998-04-02 1999-08-31 K-V Pharmaceutical Company Maximizing effectiveness of substances used to improve health and well being
PT1083879E (pt) * 1998-06-03 2005-01-31 Alza Corp Metodos e dispositivos para proporcionar uma terapia de drogas prolongada
NZ511442A (en) * 1998-11-02 2003-02-28 Elan Corp Plc Multiparticulate modified release composition for multiple dosing of ADD patients with methylphenidate HCl
US6673367B1 (en) 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US7083808B2 (en) * 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
HUP0401079A3 (en) 2001-07-10 2008-04-28 Teva Pharma Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
US20100151020A1 (en) 2008-12-16 2010-06-17 Vered Rosenberger Drug delivery system for zero order, zero order biphasic, ascending or descending drug delivery of methylphenidate

Also Published As

Publication number Publication date
US20030054033A1 (en) 2003-03-20
ATE268595T1 (de) 2004-06-15
US10463624B2 (en) 2019-11-05
US10039719B2 (en) 2018-08-07
US20090123554A1 (en) 2009-05-14
US20170135999A1 (en) 2017-05-18
EP1143937A2 (de) 2001-10-17
US8580310B2 (en) 2013-11-12
AU2122700A (en) 2000-07-03
US9066869B2 (en) 2015-06-30
US20140099361A1 (en) 2014-04-10
US6419960B1 (en) 2002-07-16
US7438930B2 (en) 2008-10-21
US20170079921A1 (en) 2017-03-23
CA2355854C (en) 2008-02-12
US10022330B2 (en) 2018-07-17
US9949931B2 (en) 2018-04-24
DE69917937T2 (de) 2005-05-25
US20170071926A1 (en) 2017-03-16
US7247318B2 (en) 2007-07-24
CA2355854A1 (en) 2000-06-22
WO2000035426A3 (en) 2000-11-09
SI1143937T1 (en) 2004-10-31
EP1143937B1 (de) 2004-06-09
US9801823B2 (en) 2017-10-31
US20180008544A1 (en) 2018-01-11
US20150313850A1 (en) 2015-11-05
JP2002532410A (ja) 2002-10-02
US20180042854A1 (en) 2018-02-15
WO2000035426A2 (en) 2000-06-22
DK1143937T3 (da) 2004-10-25
PT1143937E (pt) 2004-10-29
US20070264325A1 (en) 2007-11-15
ES2224740T3 (es) 2005-03-01
JP4172917B2 (ja) 2008-10-29

Similar Documents

Publication Publication Date Title
DE69917937D1 (de) Formulierungen mit gesteuerter freisetzung, die einen schnellen eintritt und einen schnellen abfall der wirksamen arzneistoffplasmakonzentrationen haben
CY1117845T1 (el) Ελεγχομενης/τροποποιημενης αποδεσμευσης στοματικα σκευασματα μεθυλοφαινιδατης
HRP20041152B1 (en) Pharmaceutical formulations
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
NO20006007L (no) Fremgangsmåte til dosering av et medikament, samt doseringsform
EE200300440A (et) Epotilooni analoogide ja kemoterapeutikumide kombinatsioon proliferatiivsete haiguste raviks
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
ATE284388T1 (de) Cyclpentanoindole, mischungen derartige verbindungen enthaltend und behandlungsmethoden
DE69934135D1 (de) Dosierungsformen enthaltend geschmacksmaskierten wirkstoffen
DE602004032522D1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
BRPI0411770A (pt) dispositivo aperfeiçoado de distribuição
AU8830801A (en) Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
EA200400357A1 (ru) Дезинтегрирующиеся в ротовой полости композиции валдекоксиба
DE50101364D1 (de) Ortho substituierte anthranilsäureamide und deren verwendung als arzneimittel
ID26055A (id) Senyawa-senyawa hidroksidifenil eter
PT1358177E (pt) Tratamento de desordens afectivas atraves da accao combinada de um agonista do receptor nicotinico e uma substancia manoaminergica
DE60137069D1 (de) Arzneizusammensetzungen enthaltend modafinilverbindungen
FR2848851B1 (fr) Procede d'obtention d'un principe actif presentant des capacites apaisantes, principe actif et compositions obtenues
FR2814676B1 (fr) Procede d'obtention d'un principe actif a effet tenseur immediat de la peau et principe actif obtenu
DK1273301T3 (da) Farmaceutiske præparater baseret på aktive bestanddele der kan anvendes til ulovlig administration
DK1009406T3 (da) Farmaceutisk præparat til indgivelse af thiocolchicosid gennem mundslimhinden
Wilder An essential periodontal website for dental hygienists.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition